Kathryn Guarini Sells 400 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Trading Down 1.9%

NASDAQ REGN opened at $827.72 on Friday. The business’s 50-day moving average price is $738.29 and its two-hundred day moving average price is $720.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $859.34. The firm has a market capitalization of $85.22 billion, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.65 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $12.81 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday, July 31st. HSBC decreased their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $800.36.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Brighton Jones LLC increased its position in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $226,000. Arrowstreet Capital Limited Partnership bought a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $3,183,000. Gabelli Funds LLC grew its stake in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the period. Finally, Sei Investments Co. grew its stake in Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Recent commentary continues to view Regeneron as a potentially attractive long-term biotech investment, supported by its established commercial portfolio, development pipeline and strong financial profile. However, the comparison with Vertex reportedly gives Vertex the clearer near-term investment edge. Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
• Neutral Sentiment: Regeneron’s Phase 1/2 study combining cemiplimab with SNS-101 has been completed, providing a pipeline milestone, although no efficacy or regulatory results were released. Cemiplimab Combination Trial Completion
• Negative Sentiment: Several law firms are recruiting investors for a securities class action alleging that Regeneron and certain executives misled shareholders about the viability and risks of the Phase 3 Fianlimab-Libtayo trial, including its protocol change and failure to meet the primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates potential reputational, legal and financial risks. Regeneron Class Action Deadline Alert
• Negative Sentiment: Director Kathryn Guarini sold 400 shares for $340,000, while EVP Marion McCourt sold 2,346 shares for approximately $2.0 million. All sales were made under pre-arranged Rule 10b5-1 plans, reducing their value as discretionary bearish signals, but the transactions may weigh on sentiment near recent highs. SEC Insider Transaction Filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.